Sign Up
OverviewAPI
Addex Therapeutics has called for an Extraordinary General Meeting to discuss various items, including the election of new board members and the implementation of article 20 of the company's articles of association. The meeting will focus on the lead drug candidate, ADX71149, which is in a Phase 2 clinical trial for treating epilepsy, as well as the company's licensed GABAB PAM program for substance use disorder and a broad preclinical pipeline.

Ask a question